For: | Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342 [PMID: 35979179 DOI: 10.4330/wjc.v14.i6.329] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm |
Number | Citing Articles |
1 |
Antonina Kedyk, Oleksandr Kutsyn. Metabolic effects of empagliflozine. Diabetes Obesity Metabolic Syndrome 2022; (5): 38 doi: 10.57105/2415-7252-2022-5-04
|
2 |
Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu, Jianpeng Yuan. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1028486
|
3 |
Aftab Ahmad, Hani Sabbour. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02192-4
|
4 |
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, Ghanshyam Das Gupta, Surendra H. Bodakhe, Amrita Singh. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder:
Recent Updates of Clinical and Pre-clinical Evidence. Current Diabetes Reviews 2024; 20(6) doi: 10.2174/1573399820666230809152148
|
5 |
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine 2023; 64: 102181 doi: 10.1016/j.eclinm.2023.102181
|